Literature DB >> 9694584

Identification of a point mutation associated with a silent phenotype of human serum butyrylcholinesterase--a case of familial cholinesterasemia.

N Sakamoto1, K Hidaka, T Fujisawa, M Maeda, I Iuchi.   

Abstract

A point mutation which caused a silent phenotype of human serum butyrylcholinesterase (BChE) was identified in the DNA of a 47-year-old Japanese woman who visited our hospital complaining of hypertension. The propositus exhibited an unusually low level of BChE activity, whereas her younger sister and her daughter had intermediate levels of BChE activity and her elder sister a normal level. Immunologically, the amount of BChE protein in the serum of the propositus was normal. DNA sequence analysis of the propositus identified a point mutation at codon 199 (GCA --> GTA), resulting in a Ala --> Val substitution. This alteration is one downstream codon from the catalytic active site (Ser, 198). A family study showed her younger sister and her daughter to have the same mutation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694584     DOI: 10.1016/s0009-8981(98)00058-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

Review 1.  Naturally Occurring Genetic Variants of Human Acetylcholinesterase and Butyrylcholinesterase and Their Potential Impact on the Risk of Toxicity from Cholinesterase Inhibitors.

Authors:  Oksana Lockridge; Robert B Norgren; Rudolph C Johnson; Thomas A Blake
Journal:  Chem Res Toxicol       Date:  2016-08-31       Impact factor: 3.739

2.  Butyryl-cholinesterase deficiency: A case report of delayed recovery after general anaesthesia.

Authors:  Ahmed Al-Emam
Journal:  Toxicol Rep       Date:  2021-06-17

3.  Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.

Authors:  Herve Delacour; Sofya Lushchekina; Isabelle Mabboux; Aurore Bousquet; Franck Ceppa; Lawrence M Schopfer; Oksana Lockridge; Patrick Masson
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.